RadNet (RDNT) Earning Somewhat Favorable Media Coverage, Analysis Finds
Media headlines about RadNet (NASDAQ:RDNT) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. RadNet earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 46.8253476212712 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
RDNT has been the subject of several recent analyst reports. Zacks Investment Research raised shares of RadNet from a “sell” rating to a “hold” rating in a report on Wednesday, October 25th. Jefferies Group LLC raised shares of RadNet from a “hold” rating to a “buy” rating and upped their target price for the stock from $7.00 to $12.00 in a report on Tuesday, August 22nd. BidaskClub raised shares of RadNet from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 24th. Finally, TheStreet downgraded shares of RadNet from a “b-” rating to a “c” rating in a report on Friday, October 27th.
RadNet (NASDAQ RDNT) opened at $10.05 on Friday. The company has a debt-to-equity ratio of 7.88, a current ratio of 1.29 and a quick ratio of 1.29. RadNet has a 1-year low of $5.25 and a 1-year high of $11.90. The company has a market cap of $473.90, a PE ratio of 33.83, a P/E/G ratio of 3.41 and a beta of 0.87.
RadNet (NASDAQ:RDNT) last announced its quarterly earnings results on Thursday, November 9th. The medical research company reported $0.12 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.12. RadNet had a net margin of 1.21% and a return on equity of 23.73%. The firm had revenue of $227.60 million during the quarter, compared to the consensus estimate of $232.84 million. During the same quarter last year, the firm earned $0.11 EPS. The firm’s revenue for the quarter was up 1.3% compared to the same quarter last year. research analysts expect that RadNet will post 0.35 earnings per share for the current year.
In related news, insider John V. Crues sold 40,000 shares of the stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $9.90, for a total value of $396,000.00. Following the sale, the insider now directly owns 623,781 shares of the company’s stock, valued at approximately $6,175,431.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Mark Stolper sold 10,000 shares of the stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $10.19, for a total transaction of $101,900.00. Following the completion of the sale, the vice president now directly owns 145,319 shares in the company, valued at $1,480,800.61. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,238,192 shares of company stock valued at $13,507,864. 9.36% of the stock is owned by insiders.
RadNet Company Profile
RadNet, Inc is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island.
Receive News & Ratings for RadNet Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.